← Back to Clinical Trials
Recruiting NCT05659589

NCT05659589 Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05659589
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Acute Kidney Injury
Study Type INTERVENTIONAL
Enrollment 105 participants
Start Date 2022-12-13
Primary Completion 2025-09

Trial Parameters

Condition Acute Kidney Injury
Sponsor Centre Hospitalier Universitaire, Amiens
Study Type INTERVENTIONAL
Phase N/A
Enrollment 105
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-12-13
Completion 2025-09
Interventions
blood sample

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown. The purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.

Eligibility Criteria

Inclusion Criteria: * Age over 18 years old. * Patients hospitalized in conventional hospital departments and in intensive care units of nephrology. * Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis. * AKI from functional or organic aetiology Exclusion Criteria: * Patients with severe CKD (GFR\<45ml/min/1.73 m2) or with kidney transplants. * Patients with AKI from septic or obstructive aetiology. * Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity. * Patients with sepsis or blood inflammation. * Patients with severe chronic cardia dysfunction. * Patients with arrhythmia or complete heart block. * Patients with peripheral artery occlusive disease. * Pregnancy. * Patients on palliative care.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology